BLASUBCUTANEOUSVIAL
Approved
Jun 2003
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Clinical Trials
39
Data completeness
6/8 — Strong
XOLAIR (omalizumab) by Roche is ige-directed antibody interactions [moa]. Approved for asthma, chronic spontaneous urticaria, nasal polyposis. First approved in 2003.
Drug data last refreshed 6d ago · AI intelligence enriched 2w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
XOLAIR (omalizumab) is a monoclonal antibody that binds to circulating IgE, reducing mast cell and basophil activation in allergic cascade pathways. Approved in 2003, it is indicated for IgE-mediated allergic conditions including moderate-to-severe allergic asthma and chronic idiopathic urticaria. The drug is administered via subcutaneous injection and represents a foundational biologic therapy that modulates immune response rather than treating symptoms. It occupies a niche position as a disease-modifying agent for patients with elevated baseline IgE levels.
$0.3BPart D
Mechanism of Action
IgE-directed Antibody Interactions
Pharmacologic Class:
Anti-IgE
Indications (3)
Worked on XOLAIR at Roche? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.